Meningioma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies – Merck, Chimerix, Actuate Therapeutics

September 05 21:48 2023
Meningioma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies - Merck, Chimerix, Actuate Therapeutics
Meningioma Market Outlook
DelveInsight’s “Meningioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight has launched a new report on “Meningioma – Market Insights, Epidemiology, and Market Forecast-2032”.

DelveInsight’s “Meningioma – Market Insights, Epidemiology, and Market Forecast-2032″ report deliver an in-depth understanding of the Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Meningioma Market Report:

  1. Even if comparisons are made difficult due to differences in methodologies, available annual incidence rates (gender- and age-standardized, generally on the US or World standard population), provided by population-based registries range from 1.3/100,000 to 7.8/100,000 for cerebral meningiomas. An increase in the incidence of primary brain tumors in general and of meningiomas, in particular, has been observed during the past decades in several countries. 
  2. Data from the Central Brain Tumor Registry of the United States (CBTRUS) demonstrates a more than twofold higher incidence among females [age-adjusted incidence rate (per 100,000 person-years) of 8.36 and 3.61 for females and males, respectively]. The female: male ratio of approximately 2:1 may be inverted for rare pre-pubertal meningiomas.
  3. Atypical and malignant meningiomas comprise a small fraction of the total (~5%) and have a slight male predominance. Reported rates for Black Non-Hispanics are slightly higher (6.67) than for White Non-Hispanic and Hispanics (5.90 and 5.94, respectively).

Key benefits of the report:

  1. The Meningioma market report covers a descriptive overview and comprehensive insight of the Meningioma Epidemiology and Meningioma  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Meningioma market report provides insights on the current and emerging therapies.
  3. Meningioma market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Meningioma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Meningioma market.

Got queries? Click here to know more about the Meningioma Market Landscape.

Meningioma Overview

Meningiomas are the most common benign intracranial tumor. They originate from arachnoid cap cells, which are cells within the thin, spiderweb-like membrane that covers the brain and spinal cord. The arachnoid is one of three protective layers, collectively known as the meninges, which surround the brain and the spinal cord. The other two layers of the meninges are the dura mater and pia mater. Although the majority of meningiomas are benign, these tumors can grow slowly until they are very large, if left undiscovered, and, in some locations, can be severely disabling and life-threatening. Other forms of meningioma may be more aggressive. Most patients develop a single meningioma; however, some patients may develop several tumors growing simultaneously in other locations of the brain or spinal cord.

Often, meningiomas cause no symptoms and require no immediate treatment. But the growth of benign meningiomas can cause serious problems. In some cases, such growth can be fatal. Some meningiomas are classified as atypical. These are not considered either benign or malignant (cancerous). But they may become malignant. A small number of meningiomas are cancerous. They tend to grow quickly. They also can spread to other parts of the brain and beyond, often to the lungs.

Meningioma Market 

The dynamics of the Meningioma market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Merck, Chimerix, Actuate Therapeutics, and others during the forecasted period 2019-2032.

Meningioma Pipeline Therapies and Key Companies 

  1. Keytruda: Merck
  2. ONC206: Chimerix
  3. 9-ING-41: Actuate Therapeutics

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Meningioma Patient Share (%) Overview at a Glance

5. Meningioma Market Overview at a Glance

6. Meningioma Disease Background and Overview

7. Meningioma Epidemiology and Patient Population

8. Country-Specific Patient Population of Meningioma 

9. Meningioma Current Treatment and Medical Practices

10. Unmet Needs

11. Meningioma Emerging Therapies

12. Meningioma Market Outlook

13. Country-Wise Meningioma Market Analysis (2019–2032)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Meningioma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Meningioma Market Outlook 2032.

Related Reports:

Meningioma Pipeline 

Meningioma Epidemiology 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/